Stock 9926 AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Akeso, Inc.

Equities

9926

KYG0146B1032

Market Closed - Hong Kong S.E.
Other stock markets
 09:09:00 03/05/2024 BST 		5-day change 1st Jan Change
49 HKD +0.41% Intraday chart for Akeso, Inc. +0.62% +5.60%
04-24 Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator MT
04-24 National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator
MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer
CI
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
AQ
Akeso to Raise Over HK$1 Billion Via Share Sale
MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast
MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC
CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%
MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023
CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy
MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
RE
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024
AQ
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%
MT
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
AQ
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI
CI
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
PR
Akeso, Inc. Announces Innovative Clinical Development Roadmap
CI
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy
MT
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. News Akeso, Inc.